| h-debate-a32f3a7b954 | Fractalkine Axis Restoration for Neuroprotective Signaling | 0.00 | 0.55 | CX3CL1 | proposed | 2026-04-29 | sda-2026-04-01-gap-v2-691b42f1 |
| h-debate-3c00a4d9758 | Engineered Anti-Complement Synaptic Tags | 0.00 | 0.55 | C3 | proposed | 2026-04-29 | sda-2026-04-01-gap-v2-691b42f1 |
| h-debate-fea3c767950 | Complement C1q Blockade for Selective Pruning Prevention | 0.00 | 0.55 | C1QA | proposed | 2026-04-29 | sda-2026-04-01-gap-v2-691b42f1 |
| h-debate-eb681c54a63 | TREM2 Functional Modulation for Pruning Precision | 0.00 | 0.55 | TREM2 | proposed | 2026-04-29 | sda-2026-04-01-gap-v2-691b42f1 |
| h-debate-6a4d4a8e575 | Metabolic Reprogramming of Pruning Microglia | 0.00 | 0.55 | PKM2 | proposed | 2026-04-29 | sda-2026-04-01-gap-v2-691b42f1 |
| h-debate-08b25f669c2 | Microglial Priming Reset via Short-Chain Fatty Acid Epigenetic Modulation | 0.00 | 0.55 | HDAC2, HDAC3, CD68, TREM2 | proposed | 2026-04-29 | sda-2026-04-01-003 |
| h-debate-f0d4e5cf357 | Personalized Microbiome Therapeutic Precision Medicine | 0.00 | 0.55 | Multiple individualized | proposed | 2026-04-29 | sda-2026-04-01-003 |
| h-debate-ebef2e11633 | Gut Barrier Reconstruction via Polysaccharide-Probiotic Synbiotics | 0.00 | 0.55 | CLDN1, TJP1, TLR4, NFKB1 | proposed | 2026-04-29 | sda-2026-04-01-003 |
| h-debate-ee4b4bfff9a | Glycolytic Inhibition Selectively Blocks Reactive Astrocyte Complement Productio | 0.00 | 0.55 | PFKFB3 | proposed | 2026-04-29 | sda-2026-04-01-gap-009 |
| h-debate-ea98eea802b | Hyaluronidase Treatment Disrupts Perivascular Inflammatory Niches | 0.00 | 0.55 | CD44 | proposed | 2026-04-29 | sda-2026-04-01-gap-009 |
| h-debate-3bc431ab7bb | Piezo1 Channel Inhibition Prevents Mechanical Amplification of Astrocyte Reactiv | 0.00 | 0.55 | PIEZO1 | proposed | 2026-04-29 | sda-2026-04-01-gap-009 |
| h-debate-87b23448b2e | mTOR Inhibition Promotes Astrocytic Clearance of Inflammatory Proteins | 0.00 | 0.55 | MTOR | proposed | 2026-04-29 | sda-2026-04-01-gap-009 |
| h-debate-2badd69abf6 | Timed Melatonin Administration Exploits Circadian Vulnerability of Microglial Ac | 0.00 | 0.55 | CLOCK | proposed | 2026-04-29 | sda-2026-04-01-gap-009 |
| h-debate-a47a35ffb2a | Sequential IL-1α and Complement Receptor Antagonism for Breaking Neuroinflammato | 0.00 | 0.55 | IL1A | proposed | 2026-04-29 | sda-2026-04-01-gap-009 |
| h-debate-5820d3aa5ad | Specialized Pro-Resolving Mediator Biosynthesis Enhancement in Astrocytes | 0.00 | 0.55 | ALOX15 | proposed | 2026-04-29 | sda-2026-04-01-gap-009 |
| h-debate-262ef358ac7 | Membrane Lipid Raft Reorganization Therapy | 0.00 | 0.55 | HMGCR | proposed | 2026-04-29 | SDA-2026-04-08-gap-pubmed-20260406-062207-5a703c17 |
| h-debate-d1a0ce6a506 | Cellular Stress Response Hijacking Prevention | 0.00 | 0.55 | PERK | proposed | 2026-04-29 | SDA-2026-04-08-gap-pubmed-20260406-062207-5a703c17 |
| h-debate-fff879b3edd | Chaperone Hijacking Interference Therapy | 0.00 | 0.55 | HSP70 | proposed | 2026-04-29 | SDA-2026-04-08-gap-pubmed-20260406-062207-5a703c17 |
| h-debate-3e7c779e649 | Metabolic-Complement Coupling | 0.00 | 0.55 | ATP5F1A, NDUFA1, CD55 | proposed | 2026-04-29 | SDA-2026-04-08-gap-pubmed-20260406-062128-34a47c4e |
| h-debate-999016a0046 | Synaptic Tagging Differential Vulnerability | 0.00 | 0.55 | CALR, PTDSS1, ANXA5 | proposed | 2026-04-29 | SDA-2026-04-08-gap-pubmed-20260406-062128-34a47c4e |
| h-debate-ee760695b59 | Neurotransmitter-Specific Synapse Targeting | 0.00 | 0.55 | CHAT, GAD1, C3AR1 | proposed | 2026-04-29 | SDA-2026-04-08-gap-pubmed-20260406-062128-34a47c4e |
| h-debate-17c8c7447c3 | Circuit-Specific Complement Targeting | 0.00 | 0.55 | C1QA, C3, CR1 | proposed | 2026-04-29 | SDA-2026-04-08-gap-pubmed-20260406-062128-34a47c4e |
| h-debate-2ff599b4ca3 | Microglial State-Dependent Synapse Selection | 0.00 | 0.55 | TREM2, CD68, CSF1R | proposed | 2026-04-29 | SDA-2026-04-08-gap-pubmed-20260406-062128-34a47c4e |
| h-debate-cdf5635812d | Astrocytic Complement Regulation Hypothesis | 0.00 | 0.55 | CD55, CD46, GFAP | proposed | 2026-04-29 | SDA-2026-04-08-gap-pubmed-20260406-062128-34a47c4e |
| h-debate-cc67023d5cd | Temporal Complement Activation Windows | 0.00 | 0.55 | C3AR1, C5AR1, C1QA | proposed | 2026-04-29 | SDA-2026-04-08-gap-pubmed-20260406-062128-34a47c4e |
| h-debate-784fe9aeca5 | Mitochondrial Biogenesis Reset Theory | 0.00 | 0.55 | | proposed | 2026-04-29 | SDA-2026-04-08-gap-debate-20260406-062101-7751c220 |
| h-debate-87cc4654edd | Metabolic Switch Competency Model | 0.00 | 0.55 | | proposed | 2026-04-29 | SDA-2026-04-08-gap-debate-20260406-062101-7751c220 |
| h-debate-563935a74d6 | Senescence Exit Gateway Hypothesis | 0.00 | 0.55 | | proposed | 2026-04-29 | SDA-2026-04-08-gap-debate-20260406-062101-7751c220 |
| h-debate-0f6c96d8817 | Spatiotemporal Astrocyte Subtype Gradients for Tissue Repair | 0.00 | 0.55 | Multiple | proposed | 2026-04-29 | sda-2026-04-01-gap-007 |
| h-debate-60cbd2df0ae | Epigenetic State Locking of Beneficial Astrocyte Subtypes | 0.00 | 0.55 | HDAC/BET/DNMT | proposed | 2026-04-29 | sda-2026-04-01-gap-007 |
| h-debate-1d1606a1ab9 | ARAP3-Mediated Microglial-Astrocyte Cross-Talk Modulation | 0.00 | 0.55 | ARAP3 | proposed | 2026-04-29 | sda-2026-04-01-gap-007 |
| h-debate-10f5feadbfe | Metabolic Memory Reprogramming via Molecular Switches | 0.00 | 0.55 | Undefined | proposed | 2026-04-29 | sda-2026-04-01-gap-007 |
| h-debate-d8a4f37e2e4 | Temporal Nrf2-mTOR Dual Switch Therapy | 0.00 | 0.55 | NFE2L2/MTOR | proposed | 2026-04-29 | sda-2026-04-01-gap-007 |
| h-debate-6b42d510d17 | GLP-1R-Astrocyte Axis for Cognitive Rescue | 0.00 | 0.55 | GLP1R | proposed | 2026-04-29 | sda-2026-04-01-gap-007 |
| h-debate-27e707b6d8e | Bioenergetic Checkpoint Modulation for Astrocyte Fate Control | 0.00 | 0.55 | AMPK/MTOR/SIRT1 | proposed | 2026-04-29 | sda-2026-04-01-gap-007 |
| h-debate-00e338cbe91 | Tissue-Specific Protein Complex Assembly Therapy | 0.00 | 0.55 | Tissue-specific scaffolding proteins and complex assembly fa | proposed | 2026-04-29 | SDA-2026-04-08-gap-pubmed-20260406-062222-b5f44522 |
| h-debate-8dbc1c05188 | Differential Protein Folding Environment Therapy | 0.00 | 0.55 | HSP70, HSP90, tissue-specific co-chaperones | proposed | 2026-04-29 | SDA-2026-04-08-gap-pubmed-20260406-062222-b5f44522 |
| h-debate-3d3546e2627 | Tissue-Specific Stress Response Pathway Enhancement | 0.00 | 0.55 | NRF2, ATF4, HSF1, tissue-specific stress response transcript | proposed | 2026-04-29 | SDA-2026-04-08-gap-pubmed-20260406-062222-b5f44522 |
| h-debate-e46dc8376ac | Metabolic State-Dependent Protein Function Modulation | 0.00 | 0.55 | AMPK, mTOR pathway components, tissue-specific metabolic enz | proposed | 2026-04-29 | SDA-2026-04-08-gap-pubmed-20260406-062222-b5f44522 |
| h-debate-95c109a91f7 | Ganglioside Rebalancing Therapy via ST3GAL5 Modulation | 0.00 | 0.55 | ST3GAL5 | proposed | 2026-04-29 | SDA-2026-04-04-frontier-lipidomics-dcdbc360 |
| h-debate-c4a3b6f3eef | Phosphoinositide Signaling Restoration via PIP5K1C Activation | 0.00 | 0.55 | PIP5K1C | proposed | 2026-04-29 | SDA-2026-04-04-frontier-lipidomics-dcdbc360 |
| h-debate-4d7b8789cfa | Specialized Pro-Resolving Mediator Enhancement via ALOX15 Modulation | 0.00 | 0.55 | ALOX15 | proposed | 2026-04-29 | SDA-2026-04-04-frontier-lipidomics-dcdbc360 |
| h-debate-dedb5482e61 | Very-Long-Chain Fatty Acid Normalization via ELOVL1/4 Dual Targeting | 0.00 | 0.55 | ELOVL1, ELOVL4 | proposed | 2026-04-29 | SDA-2026-04-04-frontier-lipidomics-dcdbc360 |
| h-debate-fd4c5d1435f | Ceramide-Sphingosine-1-Phosphate Axis Rebalancing via SPHK1 Enhancement | 0.00 | 0.55 | SPHK1 | proposed | 2026-04-29 | SDA-2026-04-04-frontier-lipidomics-dcdbc360 |
| h-debate-2669f584d5e | APOE Lipidation Enhancement via ABCA1 Superactivation | 0.00 | 0.55 | ABCA1 | proposed | 2026-04-29 | SDA-2026-04-04-frontier-lipidomics-dcdbc360 |
| h-debate-6a7ac6e2b89 | ATP-Mimetic Phase Separation Modulators | 0.00 | 0.55 | TARDBP | proposed | 2026-04-29 | sda-2026-04-01-gap-006 |
| h-debate-d71b812a756 | Prion-Like Domain Stabilizers via Aromatic Interaction Modulators | 0.00 | 0.55 | TARDBP | proposed | 2026-04-29 | sda-2026-04-01-gap-006 |
| h-debate-ac3b63c9a8e | Nuclear Import Receptor Enhancers | 0.00 | 0.55 | TARDBP | proposed | 2026-04-29 | sda-2026-04-01-gap-006 |
| h-debate-6d4773e443b | C9orf72 DPR Neutralizing Agents | 0.00 | 0.55 | C9orf72 | proposed | 2026-04-29 | sda-2026-04-01-gap-006 |
| h-debate-689ba7a7d15 | FcRn Transport Saturation Therapy | 0.00 | 0.55 | FCGRT | proposed | 2026-04-29 | SDA-2026-04-12-gap-debate-20260410-112908-13c403ee |